X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 24.4 39.4 61.9% View Chart
P/BV x 6.8 3.6 188.3% View Chart
Dividend Yield % 0.7 0.5 147.6%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
CIPLA
Mar-18
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs792663 119.4%   
Low Rs443479 92.5%   
Sales per share (Unadj.) Rs167.0189.0 88.4%  
Earnings per share (Unadj.) Rs38.217.6 216.9%  
Cash flow per share (Unadj.) Rs42.034.0 123.4%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.60.5 123.3%  
Book value per share (Unadj.) Rs84.9176.7 48.0%  
Shares outstanding (eoy) m188.52805.12 23.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.73.0 122.4%   
Avg P/E ratio x16.232.5 49.8%  
P/CF ratio (eoy) x14.716.8 87.6%  
Price / Book Value ratio x7.33.2 225.1%  
Dividend payout %10.517.1 61.5%   
Avg Mkt Cap Rs m116,383459,724 25.3%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m4,21426,901 15.7%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m31,487152,193 20.7%  
Other income Rs m553,577 1.5%   
Total revenues Rs m31,542155,769 20.2%   
Gross profit Rs m10,06028,264 35.6%  
Depreciation Rs m72213,228 5.5%   
Interest Rs m371,142 3.2%   
Profit before tax Rs m9,35617,470 53.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-28 5.4%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m2,1602,501 86.4%   
Profit after tax Rs m7,19414,166 50.8%  
Gross profit margin %31.918.6 172.0%  
Effective tax rate %23.114.3 161.3%   
Net profit margin %22.89.3 245.5%  
BALANCE SHEET DATA
Current assets Rs m15,066108,141 13.9%   
Current liabilities Rs m7,67438,322 20.0%   
Net working cap to sales %23.545.9 51.2%  
Current ratio x2.02.8 69.6%  
Inventory Days Days6797 69.0%  
Debtors Days Days4174 54.6%  
Net fixed assets Rs m8,237109,411 7.5%   
Share capital Rs m3771,610 23.4%   
"Free" reserves Rs m15,416140,682 11.0%   
Net worth Rs m16,005142,292 11.2%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m24,594228,606 10.8%  
Interest coverage x255.216.3 1,566.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 192.3%   
Return on assets %29.46.7 439.1%  
Return on equity %44.910.0 451.5%  
Return on capital %58.710.0 589.5%  
Exports to sales %55.732.8 170.1%   
Imports to sales %10.40-   
Exports (fob) Rs m17,55149,883 35.2%   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81151,691 34.5%   
Fx outflow Rs m5,31821,033 25.3%   
Net fx Rs m12,49330,658 40.7%   
CASH FLOW
From Operations Rs m9,30414,628 63.6%  
From Investments Rs m-3,105-8,540 36.4%  
From Financial Activity Rs m-1,959-3,855 50.8%  
Net Cashflow Rs m4,2402,431 174.4%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   MERCK LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Rupee's Fall, China's Investment Growth, and Top Stocks in Focus Today(Pre-Open)

On Tuesday, Indian share markets ended the day on a positive note with gains were largely seen in the healthcare sector, realty sector and energy sector.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS